However, the humanized monoclonal MMP-9 antibody andecaliximab is in late-stage development for cancer and auto-inflammatory disorders (14) and might improve TB outcome since the addition of an anti-MMP-9 antibody has been shown to reduce TB relapse rates in mice (15). This evidence concerns the gene MMP9 and cancer.